Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?

Abstract

The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) demonstrated that the angiotensin-converting enzyme inhibitor, perindopril, compared with placebo, in patients with established coronary artery disease, reduced cardiovascular endpoints by 20% over a four-year follow-up period. Although the authors of this study claim that the risk reduction was best explained by blockade of the renin-angiotensin-aldosterone system, reference to recent meta-analyses of blood pressure (BP)-lowering trials provides compelling evidence that the benefits observed in the trial could be explained by the 5/2 mmHg BP difference between active and placebo treatments.

Keywords

EUROPA ACE inhibitors coronary heart disease

References

Sever P. ACE inhibitors in hypertension: still a shortage of evidence. JRAAS 2000;1:117-8.

MacMahon S. , Peto R. , Cutler J. , Collins R. , Sorlie P. , Neaton J. , Abbott R. , Godwin J. , Dyer, A. , Stamler J. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990 ; 335: 765-774

Collins R. , Peto R. Antihypertensive drug therapy: Effects on Stroke and Coronary Heart Disease . In: Textbook of Hypertension. UK, Blackwell Scientific Publications, 1994; 1156-64.

Miall WE , Greenberg G. Mild hypertension: is there pressure to treat? An account of the MRC trial . Cambridge: Cambridge University Press. 1987;78-152.

Grimm RH , Leon AS , Hunninghake DB , Lenz K. , Hannan P. , Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med 1981 :94:7-11.

Staessen, JA , Fagard R. , Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.

Nayler WG Review of preclinical data of calcium channel blockers and atherosclerosis . J Cardiovasc Pharmacol 1999; 33(suppl 2):S7-S11.

Opie L. Angiotensin-converting enzyme inhibitors: the advances continue. NewYork:Authors' Publishing House, 1999.

Hansson L. , Lindholm LH , Niskanen L. et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial . Lancet 1999;353:611-16.

10.

Hansson L. , Lindholm LH , Ekborn T. et al., for the STOP-2 Hypertension Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.

11.

Brown MJ , Palmer CR , Castaigne A. , de Leeuw PW , Mancia G. , Rosenthal T. , Ruilope LM Morbidity and mortality in patients randomised to double-blind treatment with a long-actingcalcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) . Lancet 2000;356:366-72.

12.

Hansson L. , Hedner T. , Lund-Johansen P. et al. Randomised trial of the effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension on the Nordic Diltiazem study NORDIL. Lancet 2000;356:359-65.

13.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002: 23: 2981-97

14.

Blood Pressure Lowering TreatmentTrialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.

15.

EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.

16.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl JMed 2000;342: 145-53.

17.

Williams B.

The renin angiotensin system and cardiovascular disease: hope or hype?

JRAAS 2000; 1:142-6.

18.

Svenson P. , de Faire U. , Sleight P. , Yusuf S. , Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures; a HOPE Substudy. Hypertension 2001;38: e28.

19.

White HD Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Commentary. Lancet 2003;362:755-7.

20.

Mann J. , Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.

21.

Sever P. , Dahlof B. , Poulter N. et al., for the ASCOT Investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001;19:1139-47.